Semaglutide, a GLP-1 receptor agonist marketed by Novo Nordisk under the names Wegovy and Ozempic, has demonstrated significant health benefits for patients with both type 2 diabetes and peripheral artery disease (PAD), according to results from the STRIDE clinical trial. Presented at the American College of Cardiology (ACC) Annual Meeting, these findings highlight the potential of semaglutide to improve outcomes in this challenging patient population.
The STRIDE trial, involving nearly 800 patients across North America, Asia, and Europe, found that semaglutide led to a 40-meter improvement in maximum walking distance after one year compared to placebo. This benefit was consistent across various demographic groups, including age, sex, and body mass index. Additionally, semaglutide was associated with improvements in pain-free walking distance and sustained walking capacity even after discontinuing the drug.
Semaglutide is the first treatment for PAD and type 2 diabetes to significantly reduce major adverse cardiovascular events and improve both cardiometabolic and kidney outcomes, alongside enhancing walking capacity and quality of life. The study’s findings were published in The Lancet.
Clinicians at ACC.25, including Dr. Josha Beckman and Dr. Kim Eagle, hailed these results as groundbreaking, noting the substantial impact on patients’ daily lives. Novo Nordisk expressed its commitment to advancing cardiometabolic science and improving clinical outcomes for patients with this pivotal data.
Follow MEDWIRE.AI for more insights into cardiometabolic advancements.
